医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Dr. Alan Snow from ProteoTech to Present at the XIV International Symposium on Amyloidosis

2014年05月01日 AM08:00
このエントリーをはてなブックマークに追加


 

KIRKLAND, Wash.

ProteoTech Inc. (ProteoTech) today announced that Dr. Alan Snow, ProteoTech’s President & Chief Scientific Officer will present an oral presentation at the XIV International Symposium on Amyloidosis.

Dr. Snow’s presentation at the XIV International Symposium on Amyloidosis (Indianapolis, IN) will take place on Thursday May 1, 2014 and is entitled “The Small Molecule SystebrylTM (PTI-110) Causes Potent Disaggregation/Reduction of AL, TTR and AA Amyloidosis”. The International Symposium on Amyloidosis is held every two years and brings together the top amyloid researchers in the world. Dr. Snow will discuss ProteoTech’s lead compound, SystebrylTM (PTI-110) and its ability to disaggregate and reduce amyloid fibril deposits of the AL (immunoglobulin light chain), TTR (transthyretin) and AA (inflammation-associated amyloidosis; AA amyloid) amyloid types.

ProteoTech is a private, therapeutic development Company that utilizes its amyloid expertise to discover and develop new drugs for treating misfolding protein disorders and amyloid diseases. ProteoTech’s lead small molecule compound, Systebryl (PTI-110) will soon be entering Phase 1/2 proof-of-concept studies in AL (immunoglobulin light chain) amyloidosis (an orphan disease). Other drugs in the pipeline, include a small molecule drug inhibitor for TTR (transthyretin) amyloidosis, a small molecule drug inhibitor of alpha-synuclein accumulation (for Parkinson’s disease and other synucleinopathies), and a small molecule drug that works both on the beta-amyloid protein and tau protein of Alzheimer’s disease. For further information, please contact Dr. Roger Flugel, Chief Business Officer (flugel@proteotech.com) or Dr. Alan Snow, President & Chief Scientific Officer (snow@proteotech.com).

For more information: http://www.proteotech.com

CONTACT

ProteoTech Inc.
Chief Business Officer
Dr. Roger Flugel,
425-823-0400
flugel@proteotech.com
or
President
& Chief Scientific Officer
Dr. Alan Snow, 425-823-0400
snow@proteotech.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • レスメド後援の研究で在宅酸素療法と在宅非侵襲的換気療法の併用が費用対効果の高いCOPD治療法であると判明
  • Takeda to Highlight Broad Oncology Portfolio and Pipeline Data at the American Society of Clinical Oncology (ASCO) and the Congress of the European Hematology Association (EHA) Annual Meetings
  • Cerveau Technologies, Inc.与日本东京都老人综合研究所签订研究协议
  • 继美国和英国之后,中国向Personalis, Inc.签发ACE©技术专利,扩大了其在国际上的知名度
  • セルヴォー・テクノロジーズが日本の東京都健康長寿医療センター研究所と研究契約を締結